Start free trial
Trending New Genres Authors
EnglishEnglish
EspañolSpanish
简体中文Chinese
繁體中文Chinese (Traditional)
FrançaisFrench
DeutschGerman
日本語Japanese
PortuguêsPortuguese
ItalianoItalian
한국어Korean
РусскийRussian
NederlandsDutch
العربيةArabic
PolskiPolish
हिन्दीHindi
Tiếng ViệtVietnamese
SvenskaSwedish
ΕλληνικάGreek
TürkçeTurkish
ไทยThai
ČeštinaCzech
RomânăRomanian
MagyarHungarian
УкраїнськаUkrainian
IndonesiaIndonesian
DanskDanish
SuomiFinnish
БългарскиBulgarian
עבריתHebrew
NorskNorwegian
HrvatskiCroatian
CatalàCatalan
SlovenčinaSlovak
LietuviųLithuanian
SlovenščinaSlovenian
СрпскиSerbian
EestiEstonian
LatviešuLatvian
فارسیPersian
മലയാളംMalayalam
தமிழ்Tamil
اردوUrdu
Searching...
SoBrief
The Devil's Playbook

The Devil's Playbook

Big Tobacco, Juul, and the Addiction of a New Generation
Altria paid $12.8 billion for Juul, then discovered the costs of owning a youth-vaping crisis.
by Lauren Etter 2021 495 pages
4.14
500+ ratings
Listen
Immersive
V2.3
Amazon Kindle Audible
Try Full Access for 3 Days
Unlock listening & more!
Continue

Key Takeaways

A safer nicotine product can still ignite a public-health crisis

The alternative had merit. Harm reduction means lowering the damage caused by a risky behavior when stopping it altogether is difficult. Burning tobacco creates most of the deadly toxins in cigarette smoke; smoking kills roughly 480,000 Americans a year. Nicotine is addictive, but it is not the main cause of smoking-related cancers. Stanford designers James Monsees and Adam Bowen saw a chance to deliver nicotine without burning tobacco, potentially giving adult smokers a less harmful alternative.

The audience changes the arithmetic. A product may reduce risk for a smoker who switches completely, yet increase harm if it draws people who otherwise would not use nicotine, especially teenagers. The book’s central question is therefore not whether vaping is identical to smoking. It is whether reduced danger for some users outweighs new addiction and exposure across the population.

Analysis

What's striking is the clash between two valid measures of success. A clinician may focus on whether an individual smoker lowers their risk; a public-health agency must also count how many people start using nicotine at all. Those measures can point in opposite directions. This resembles the prevention paradox in epidemiology: a small risk spread across a very large population can create substantial harm. The book makes the trade-off vivid, though the comparison depends on reliable evidence about who switches, who initiates, and how much risk each product actually carries.

Treat social permission as a business constraint, not a PR problem

Trust was a survival issue. Tobacco companies spent decades disputing evidence about smoking, addiction, and youth marketing. After a 1953 study linked cigarettes to cancer, industry leaders planned a coordinated effort to discredit the findings. In 1994, seven tobacco CEOs testified to Congress that they did not believe nicotine was addictive, despite extensive contrary evidence. Litigation, whistleblowers, and public scrutiny eventually made that posture untenable.

The pivot came under pressure. The 1998 Master Settlement Agreement required major companies to pay states an estimated $206 billion by 2025 and imposed restrictions aimed at youth marketing. In 1999, Philip Morris executive Steve Parrish trained employees to engage with critics rather than retreat into a corporate bunker. The company’s new language of responsibility was strategic as well as moral: executives understood that continued operation depended on public acceptance.

Analysis

The case illustrates a social license to operate: legal permission is not enough if customers, regulators, and communities view a business as illegitimate. Research on organizational trust suggests that apologies and new slogans do little when they are not matched by verifiable changes in conduct. That distinction matters here because the company’s shift toward engagement was triggered partly by litigation and risk to its business. Strategic adaptation can still produce real change, but the motive alone cannot establish that trust has been earned.

Innovation can rediscover what an industry's archives already know

The past was searchable. Bowen and Monsees began developing a new smoking device as Stanford product-design students. Research in a public archive of tobacco-company records, ultimately containing more than 90 million pages, showed that Big Tobacco had spent decades trying to make cigarettes that heated rather than burned tobacco. Products such as Reynolds’ Premier and Philip Morris’ Accord failed to attract consumers, but the experiments left behind technical knowledge and patents.

A new team revived the problem. The founders initially designed Ploom, a portable heated-tobacco device, and later shifted toward electronic cigarettes. Their early product was cumbersome and delivered too little nicotine, but their willingness to combine design, engineering, and chemistry helped them keep searching. Philip Morris, meanwhile, had examined China’s Ruyan e-cigarette and dismissed it. The contrast was not simply between clever newcomers and a foolish incumbent: the incumbent had relevant knowledge but struggled to turn it into a compelling product.

Analysis

This is a useful corrective to the myth that disruption happens because outsiders possess information insiders lack. Often the knowledge already exists inside an industry, but incentives, organizational habits, or reputational fears prevent it from being recombined. The archive also gave the founders an unusual advantage: they could learn from failed experiments without paying for them. Yet historical technical work is not the same as proof of safety. Reusing old science can accelerate invention, but it can also carry forward assumptions that were never adequately tested.

Make nicotine smoother, and users can inhale far more of it

Chemistry changed the experience. Freebase nicotine, a relatively alkaline form, can feel harsh when inhaled. Bowen, Monsees, and chemist Chenyue Xing explored adding organic acids to the nicotine liquid. The resulting nicotine salts lowered its pH, making a concentrated dose smoother to inhale. The technical insight drew on decades of tobacco research into how acidity affects a cigarette’s flavor and throat sensation.

Delivery speed mattered. In a New Zealand human study, the team compared nicotine formulations with cigarettes and measured nicotine in participants’ blood. A benzoic-acid formulation produced rapid absorption and high satisfaction ratings. Juul’s commercial pods eventually contained 5 percent nicotine; the book reports that a small pod delivered roughly as much nicotine as a pack of cigarettes. The design solved a problem for smokers seeking a substitute, but also made frequent, discreet use easy and dependence harder to recognize.

Analysis

The story shows how product design can alter pharmacology, not merely packaging. A smoother experience lowers the immediate sensory barrier, while rapid delivery can reinforce repeated use. Behavioral science describes this as a tightly coupled reward: the shorter the gap between an action and its effect, the easier the behavior is to repeat. That does not make every high-dose product inherently unacceptable, particularly for adult smokers seeking an alternative. It does make dose, delivery speed, and user population central safety questions, not secondary engineering details.

A product's intended audience does not control who its design attracts

The launch sold a lifestyle. Juul’s 2015 campaign featured young-looking models, fashion imagery, parties, and a sleek device displayed like a consumer gadget. The company distributed hundreds of thousands of free pods and relied on social media and influencers to spread awareness. Executives described the product as an alternative for adult smokers, but its compact shape, flavors, discreet vapor, and online buzz also made it attractive to teenagers.

The warning signs appeared early. Juul’s own systems made it possible to order products online with weak age checks, and a warranty process could be exploited to obtain free devices. Teenagers created fan accounts and shared ways to hide Juuls at school. By 2018, more than three million high school students reported using e-cigarettes, a sharp increase from the prior year. The gap between stated target and actual audience was not a minor marketing error; it became a central threat to the company.

Analysis

This is a classic problem of platform growth: a company can design for one user group while distribution networks and social imitation carry the product elsewhere. In networked markets, user-generated promotion is difficult to confine to a carefully defined demographic. That makes audience claims weaker than evidence about actual reach and use. The point is not that every attractive design targets children. Rather, when a product contains an addictive substance, youth appeal and access need to be assessed before a viral launch, not treated as cleanup after success.

Regulatory delay turned a temporary loophole into a national nicotine laboratory

The rules lagged behind the product. The 2009 Tobacco Control Act gave the FDA authority over tobacco products, but e-cigarettes were not clearly included at first. A court ruling blocked the agency from regulating them as drug devices when marketed for recreational use. The FDA eventually brought them under tobacco rules through its 2016 deeming rule, which restricted sales to minors and required agency review before products could remain on the market.

Delay left room to grow. In 2017, FDA Commissioner Scott Gottlieb extended the deadline for applications from 2018 to 2022, giving companies four more years to sell products without authorization. In 2018, youth e-cigarette use rose nearly 80 percent, reaching more than three million high school students. Meanwhile, the rule made even small product changes legally consequential. Juul quietly redesigned a faulty device rather than wait for a potentially lengthy approval process, putting growth and compliance into direct conflict.

Analysis

Regulation here is not simply a contest between innovation and bureaucracy. Delay can create a de facto policy choice: products spread first, and the evidence and rules catch up later. That approach may preserve adult access to promising alternatives, but it shifts uncertainty onto consumers, schools, and public agencies. A more adaptive system could require stronger safeguards early, then revise them as evidence accumulates. The book also makes clear that rules can produce unintended effects: a design freeze meant to control new products can discourage companies from correcting defects.

Altria spent $12.8 billion to buy a runaway it could not steer

The deal promised access and speed. In December 2018, tobacco giant Altria paid $12.8 billion for a 35 percent stake in Juul, valuing the start-up at $38 billion. Altria offered retail reach, regulatory experience, and access to a vast customer base. Juul offered the leading e-cigarette brand and a product that Altria had failed to build. The agreement also included $1 billion in employee bonuses, helping retain a workforce that might otherwise have rejected the tobacco company’s involvement.

The risks arrived with the investment. Altria had pulled its own MarkTen products from the market, a move that later became part of an antitrust investigation. It did not gain control of Juul, yet it inherited reputational and legal exposure as youth use, regulation, and public backlash intensified. Within about a year, Altria wrote down the investment by $4.5 billion, then took another $4.1 billion impairment. The acquisition bought a stake in growth, but not control over the conditions that made the growth possible.

Analysis

The deal exposes a familiar corporate-finance trap: paying for a growth story while assuming the buyer can manage away the risks that produced it. Altria had assets Juul lacked, but those assets could not erase the start-up’s accumulated reputational liabilities. Minority ownership further complicated accountability because the investor bore exposure without full operational authority. The transaction also shows how valuation can become detached from governance: a market may reward rapid adoption before it has priced in regulatory, health, and litigation costs.

Growth targets made safety controls look like obstacles

Scaling exposed weak systems. Juul’s rapid expansion strained manufacturing and quality control. Customers reported leaking pods, inconsistent flavors, and device failures. Employees discovered problems including mislabeled products, separated ingredients, and metal fragments caught before they reached consumers. The company sometimes relied on staff to taste-test formulations before complete toxicology reviews. When a questionable batch was found, executives debated how much to discard rather than defaulting to a full recall.

The culture rewarded momentum. Juul grew from a small start-up into a global company, but operational controls did not mature at the same pace. Its leaders faced pressure to meet sales forecasts, expand distribution, and satisfy investors. Some employees began questioning whether the product’s ingredients and long-term effects were adequately understood. This was not proof that every Juul product caused injury, nor that every quality defect was dangerous. It did reveal a mismatch between the company’s scale and its ability to detect, investigate, and disclose problems consistently.

Analysis

Safety engineering depends on more than good intentions; it requires repeatable processes, clear authority to stop production, and incentives that reward reporting bad news. High-reliability organizations treat near misses as valuable data, while growth companies can treat them as friction. That difference becomes especially important when a product is inhaled and long-term effects are unknown. The account does not establish that every reported complaint was caused by Juul, but it shows why sound controls matter even before causal certainty is available.

Judge harm reduction by who switches, who starts, and what evidence supports safety

The health picture was mixed. E-cigarettes may offer adult smokers a less dangerous alternative to combustible cigarettes, but the book describes serious uncertainty about long-term inhalation risks and a steep rise in youth nicotine use. In 2019, a lung-injury outbreak called EVALI sickened thousands and caused deaths. Investigators found vitamin E acetate in lung samples, pointing strongly toward illicit THC vaping products as a major cause. The evidence did not establish Juul as the principal cause, though some patients reported using nicotine products alone.

The public-health test is broader than one device. By 2020, 3.6 million young people still used e-cigarettes, and nearly a quarter of them reported daily use. A policy must weigh potential benefit for adult smokers against initiation among people who never smoked, dependence among teenagers, and uncertainty about chronic exposure. Juul’s rise and retreat left regulators with a difficult choice: permit a potentially lower-risk substitute, restrict a product implicated in youth addiction, or try to distinguish the two through evidence and enforcement.

Analysis

The strongest way to evaluate harm reduction is with counterfactuals: what would each user likely have done without the product, and what happens after switching? That requires longitudinal evidence, not just chemistry or sales data. It also requires separating legal nicotine products from illicit THC products when investigating illness. The distinction matters because broad claims that vaping either saves lives or causes the outbreak oversimplify the evidence. A credible policy must protect adult smokers without making a new generation of nicotine users the price of that protection.

Analysis

The book’s deepest argument is about a collision between three systems that operate on different clocks. Nicotine acts quickly, reinforcing use within seconds. Venture-backed companies seek rapid adoption and valuation growth. Public-health evidence and regulation develop slowly, often after a product has already reached millions of people. Juul succeeded by aligning the first two clocks while the third lagged. Its nicotine formulation, compact design, and marketing made the product unusually easy to adopt; its growth then outpaced the safeguards needed to understand and manage its reach.

The historical thread matters because Juul did not invent the underlying commercial logic. Tobacco companies had long studied how to optimize nicotine delivery, shape sensory experience, recruit younger customers, and defend their social legitimacy. Yet the book avoids reducing the founders to simple imitators of Big Tobacco. Their stated harm-reduction ambition was plausible, and the product may have helped some adult smokers move away from combustible cigarettes. The failure was that this intention became a moral license for behaviors whose consequences were not measured carefully enough.

That distinction complicates the usual hero-versus-villain story. Altria’s prior caution was shaped by decades of litigation and public disgrace, but caution did not make it an effective innovator. Juul’s speed enabled technical breakthroughs, yet speed also weakened quality control and let youth appeal become a crisis. The acquisition then joined the companies’ weaknesses: Altria brought tobacco’s history and regulatory expertise, while Juul brought the growth machine and its liabilities. Neither possessed a credible way to control the combined risks.

The book also highlights a measurement problem. Sales, market share, and conversion rates are easy to quantify; avoided deaths, newly created dependence, and future lung effects are harder. When firms optimize for the visible metrics, costs that are delayed or distributed across families and public institutions become easy to discount. The practical lesson is not that every risky innovation should be blocked. It is that products affecting addiction, youth, and public health require evidence and safeguards proportionate to their power, before growth makes restraint politically and commercially difficult.

Summary in 30 Seconds
Vaping may reduce harm for adult smokers who switch completely, but it can also draw new users into nicotine dependence. Smoother nicotine salts made high doses easier to inhale, while compact devices, flavors, and discreet vapor appealed to teenagers. Regulatory delays gave products time to spread: more than three million high school students used e-cigarettes by 2018. Rapid growth strained quality controls, and Altria's $12.8 billion investment could not contain the resulting risks.
Contains spoilers

Last updated:

Report Issue

Review Summary

4.14 out of 5
Average of 500+ ratings from Goodreads and Amazon.

The Devil's Playbook receives mixed reviews, with an overall rating of 4.15/5. Readers praise the book's in-depth investigation of the e-cigarette industry, particularly Juul's rise and fall. Many find it compelling and well-researched, offering insights into corporate greed and public health concerns. However, some criticize its dense information and slow pacing. The book is commended for its exploration of Big Tobacco's tactics and the complexities of regulating new nicotine products. While informative, some readers found it challenging to follow due to numerous characters and details.

Your rating:
4.45
104 ratings
Want to read the full book?

Glossary

Harm reduction

Lowering harm without abstinence

A public-health approach that seeks to reduce injury from a behavior even when eliminating that behavior is difficult or unlikely. In the book, the idea is applied to nicotine: adults who cannot or will not quit might move from combustible cigarettes to products that avoid burning tobacco. The approach depends on whether the alternative actually reduces harm and whether it creates new users.

Continuum of risk

Ranking nicotine products by harm

A framework that places nicotine products along a range according to their expected health risks. Combustible cigarettes sit toward the more harmful end because burning tobacco produces toxic smoke. Medicinal nicotine products such as patches and gum sit toward the less harmful end. E-cigarettes fall between them, where potential benefits for smokers must be weighed against uncertain health effects and youth use.

Nicotine salts

Acid-adjusted nicotine formulation

A form of nicotine created by combining nicotine with an organic acid. The added acid lowers the formulation’s pH and can make concentrated nicotine less harsh to inhale than freebase nicotine. Juul used a benzoic-acid formulation to deliver a strong nicotine dose with a smoother sensation, helping its product feel more satisfying to smokers.

Deeming rule

FDA extension of tobacco oversight

The FDA’s 2016 rule bringing e-cigarettes and several other previously uncovered products under the federal tobacco-control framework. It restricted sales to minors, barred free samples, required warnings and ingredient reporting, and established a premarket review process. Existing products received a period to remain on sale while seeking authorization, and the rule limited changes to products during that period.

Premarket tobacco product application

FDA application to sell a product

An application manufacturers submit to the FDA seeking permission to market a new tobacco product. The agency evaluates whether the product is appropriate for the protection of public health, considering its potential effects on users and nonusers. The review process can require extensive scientific evidence, making authorization a central question for companies selling newer nicotine products.

EVALI

Vaping-associated lung injury

An acronym for e-cigarette or vaping product use-associated lung injury, the name given to a 2019 outbreak of severe respiratory illness. Investigators found vitamin E acetate in lung samples from patients, strongly linking the outbreak to illicit THC vaping products. The investigation did not establish that Juul was the principal cause, and uncertainty remained about some cases involving nicotine products.

Product/market fit

Strong demand for a product

A start-up concept describing the point when a product meets a clear market need and customers adopt it rapidly. In the book, Juul’s repeat purchases, retailer demand, and difficulty keeping products in stock signaled strong product/market fit. The same demand was also tied to nicotine’s addictive properties, making the usual start-up success measure ethically and socially complicated.

Societal alignment

Keeping business acceptable to society

Philip Morris’s language for adapting company conduct and public engagement to social expectations after the Tobacco Wars. It included listening to criticism, addressing contentious issues, and preserving the company’s permission to operate. The term could describe constructive organizational change, but it also served a strategic purpose by helping protect the company’s brands and future business.

About the Author

Lauren Etter is an accomplished investigative journalist currently working for Bloomberg News. Her expertise lies in writing comprehensive corporate features and investigative stories. Prior to her current role, Etter was a staff reporter at The Wall Street Journal and has contributed to prestigious publications such as Vanity Fair and The New Yorker. Her educational background includes master's degrees in both journalism and law from Northwestern University. Etter's investigative skills and in-depth reporting are evident in her work, particularly in "The Devil's Playbook," which showcases her ability to unravel complex corporate narratives and their societal impacts.

Download PDF

To save this The Devil's Playbook summary for later, download the free PDF. You can print it out, or read offline at your convenience.
Download PDF
File size: 0.32 MB     Pages: 15

Download EPUB

To read this The Devil's Playbook summary on your e-reader device or app, download the free EPUB. The .epub digital book format is ideal for reading ebooks on phones, tablets, and e-readers.
Download EPUB
File size: 1.37 MB     Pages: 20
Want to read the full book?
Follow
Listen
Home
Swipe
Library
Get App
Try Full Access for 3 Days
Listen, bookmark, and more
Compare Features Free Pro
📖 Read Summaries
Read unlimited summaries. Free users get 3 per month
🎧 Listen to Summaries
Listen to unlimited summaries in 40 languages
—
❤️ Unlimited Bookmarks
Free users are limited to 4
—
📜 Unlimited History
Free users are limited to 4
—
📥 Unlimited Downloads
Free users are limited to 1
—
Risk-Free Timeline
Today: Get Instant Access
Listen to full summaries of 26,000+ books. That's 12,000+ hours of audio!
Day 2: Trial Reminder
We'll send you a notification that your trial is ending soon.
Day 3: Your subscription begins
You'll be charged on Nov 24,
cancel anytime before.
Consume 2.8× More Books
2.8× more books Listening Reading
Our users love us
1M+ readers
Trustpilot Rating
TrustPilot
4.6 Excellent
This site is a total game-changer. I've been flying through book summaries like never before. Highly, highly recommend.
— Dave G
Worth my money and time, and really well made. I've never seen this quality of summaries on other websites. Very helpful!
— Em
Highly recommended!! Fantastic service. Perfect for those that want a little more than a teaser but not all the intricate details of a full audio book.
— Greg M
Save 62%
Yearly
$119.88 $44.99/year/yr
$3.75/mo
Monthly
$9.99/mo
Start a 3-Day Free Trial
3 days free, then $44.99/year. Cancel anytime.
Unlock a world of fiction & nonfiction books
26,000+ books for the price of 2 books
Read any book in 10 minutes
Discover new books like Tinder
Request any book if it's not summarized
Read more books than anyone you know
#1 app for book lovers
Lifelike & immersive summaries
30-day money-back guarantee
Download summaries in EPUBs or PDFs
Cancel anytime in a few clicks

Why one summary?

Scanner
Find a barcode to scan

⭐
⭐
⭐
We have a special gift for you
Open
38% off
DISCOUNT FOR YOU
⭐
⭐
⭐
$79.99
$49.99/year
Only $4.16 per month
Continue
2 taps to start, super easy to cancel
Settings
General
Widget
Loading...